There has been limited exploration of blood-based biomarkers in the chronic period following traumatic brain injury (TBI). Our objective was to conduct a systematic review of studies examining blood-based protein biomarkers with at least one sample collected 12 months post-TBI in adults (≥16 years). Database searches were conducted in Embase, MEDLINE, and Science Citation Index–Expanded on July 24, 2023. Risk of bias was assessed using modified Joanna Briggs Institute critical appraisal tools. Only 30 of 12,523 articles met inclusion criteria, with samples drawn from 12 months to 48 years. Higher quality evidence (low risk of bias; large samples) identified promising inflammatory biomarkers at 12 months post-injury in both moderate-severe TBI (GFAP) and mild TBI (eotaxin-1, IFN-y, IL-8, IL-9, IL-17A, MCP-1, MIP-1β, FGF-basic, and TNF-α). Studies with low risk of bias but smaller samples also suggest NSE, MME, and CRP may be informative, alongside protein variants for α-syn (10H, D5), amyloid-β (A4, C6T), TDP-43 (AD-TDP 1;2;3;9;11), and tau (D11C). Findings for NfL were inconclusive. Longitudinal data were mostly available for acute samples followed until 12 months post-injury, with limited evaluation of changes beyond 12 months. Associations of some blood-based biomarkers with cognitive, sleep, and functional outcomes were reported. The overall strength of the evidence in this review was limited by the risk of bias and small sample sizes. Replication is required within prospective longitudinal studies that move beyond 12 months post-injury. Novel efforts should be guided by promising neurodegenerative-disease markers and use panels to model polypathology.
Get full access to this article
View all access options for this article.
References
1.
MaasAIR, MenonDK, AdelsonPD, et al;InTBIR Participants and Investigators. Traumatic brain injury: Integrated approaches to improve prevention, clinical care, and research. Lancet Neurol, 2017; 16(12):987–1048; doi: 10.1016/S1474-4422(17)30371-X
2.
BrazinovaA, RehorcikovaV, TaylorMS, et al.Epidemiology of traumatic brain injury in Europe: A living systematic review. J Neurotrauma, 2021; 38(10):1411–1440; doi: 10.1089/neu.2015.4126
3.
Centers for Disease Control and Prevention. Surveillance Report of Traumatic Brain Injury-Related Hospitalizations and Deaths by Age Group, Sex, and Mechanism of Injury—United States, 2016 and 2017. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; 2021.
4.
GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol, 2019; 18(1):56–87; doi: 10.1016/S1474-4422(18)30415-0
5.
SilverbergND, IversonGL, CoganA, et al;ACRM Brain Injury Special Interest Group Mild TBI Task Force members. The American congress of rehabilitation medicine diagnostic criteria for mild traumatic brain injury. Arch Phys Med Rehabil, 2023; 104(8):1343–1355; doi: 10.1016/j.apmr.2023.03.036
6.
CifuD, HurleyR, PetersonM, et al.Clinical practice guideline: Management of concussion/mild traumatic brain injury. J Rehabil Res Dev, 2009; 46(6):CP1; doi: 10.1682/jrrd.2009.06.0076
SmithC, GentlemanSM, LeclercqPD, et al.The neuroinflammatory response in humans after traumatic brain injury. Neuropathol Appl Neurobiol, 2013; 39(6):654–666; doi: 10.1111/nan.12008
9.
Abdul-MuneerPM, ChandraN, HaorahJ. Interactions of oxidative stress and neurovascular inflammation in the pathogenesis of traumatic brain injury. Mol Neurobiol, 2015; 51(3):966–979; doi: 10.1007/s12035-014-8752-3
10.
BlennowK, HardyJ, ZetterbergH. The neuropathology and neurobiology of traumatic brain injury. Neuron, 2012; 76(5):886–899; doi: 10.1016/j.neuron.2012.11.021
11.
MarklundN, TenovuoO. Pathophysiology of severe traumatic brain injury. Management of Severe Traumatic Brain Injury, 2020:35–50; doi: 10.1007/978-3-030-39383-0_6
12.
WilsonL, StewartW, Dams-O’ConnorK, et al.The chronic and evolving neurological consequences of traumatic brain injury. Lancet Neurol, 2017; 16(10):813–825; doi: 10.1016/S1474-4422(17)30279-X
13.
CorriganJD, HammondFM. Traumatic brain injury as a chronic health condition. Arch Phys Med Rehabil, 2013; 94(6):1199–1201; doi: 10.1016/j.apmr.2013.01.023
14.
MaselBE, DeWittDS. Traumatic brain injury: A disease process, not an event. J Neurotrauma, 2010; 27(8):1529–1540; doi: 10.1089/neu.2010.1358
15.
HicksAJ, SpitzG, RoweCC, et al.Does cognitive decline occur decades after moderate to severe traumatic brain injury? A prospective controlled study. Neuropsychol Rehabil, 2022; 32(7):1530–1549; doi: 10.1080/09602011.2021.1914674
16.
CorkinS, RosenTJ, SullivanEV, et al.Penetrating head injury in young adulthood exacerbates cognitive decline in later years. J Neurosci, 1989; 9(11):3876–3883.
17.
RaymontV, SalazarAM, LipskyR, et al.Correlates of posttraumatic epilepsy 35 years following combat brain injury. Neurology, 2010; 75(3):224–229; doi: 10.1212/wnl.0b013e3181e8e6d0
18.
CumminsT, EliasA, LambF, et al.Cognitive deficits four decades after moderate to severe, but not mild traumatic brain injury in Vietnam war veterans. Global Psychiatry, 2021.
19.
DraperK, PonsfordJL. Cognitive functioning ten years following traumatic brain injury and rehabilitation. Neuropsychology, 2008; 22(5):618–625; doi: 10.1037/0894-4105.22.5.618
20.
HoofienD, GilboaA, VakilE, et al.Traumatic brain injury (TBI) 10–20 years later: A comprehensive outcome study of psychiatric symptomatology, cognitive abilities and psychosocial functioning. Brain Inj, 2001; 15(3):189–209; doi: 10.1080/026990501300005659
21.
AndelicN, HoweEI, HellstrømT, et al.Disability and quality of life 20 years after traumatic brain injury. Brain Behav, 2018; 8(7):e01018; doi: 10.1002/brb3.1018
22.
DahmJ, PonsfordJL. Comparison of long-term outcomes following traumatic injury: What is the unique experience for those with brain injury compared with orthopaedic injury? Injury, 2015; 46(1):142–149; doi: 10.1016/j.injury.2014.07.012
23.
HicksAJ, GouldKR, HopwoodM, et al.Behaviours of concern following moderate to severe traumatic brain injury in individuals living in the community. Brain Inj, 2017; 31(10):1312–1319; doi: 10.1080/02699052.2017.1317361
24.
PonsfordJL, DowningM, OlverJ, et al.Longitudinal follow-up of patients with traumatic brain injury: Outcome at two, five, and ten years post-injury. J Neurotrauma, 2014; 31(1):64–77; doi: 10.1089/neu.2013.2997
25.
BrettBL, TemkinN, BarberJK, et al;for TRACK-TBI Investigators. Long-term multidomain patterns of change after traumatic brain injury: A TRACK-TBI LONG study. Neurology, 2023; 101(7):e740–e753; doi: 10.1212/WNL.0000000000207501
26.
Dams-O’ConnorK, JuengstSB, BognerJ, et al.Traumatic brain injury as a chronic disease: Insights from the United States traumatic brain injury model systems research program. Lancet Neurol, 2023; 22(6):517–528; doi: 10.1016/S1474-4422(23)00065-0
27.
SimanR, McIntoshTK, SolteszKM, et al.Proteins released from degenerating neurons are surrogate markers for acute brain damage. Neurobiol Dis, 2004; 16(2):311–320; doi: 10.1016/j.nbd.2004.03.016
28.
MarchiN, CavagliaM, FazioV, et al.Peripheral markers of blood–brain barrier damage. Clin Chim Acta, 2004; 342(1–2):1–12; doi: 10.1016/j.cccn.2003.12.008
29.
MarchiN, RasmussenP, KapuralM, et al.Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor Neurol Neurosci, 2003; 21(3–4):109–121.
30.
JessenNA, MunkASF, LundgaardI, et al.The glymphatic system: A beginner’s guide. Neurochem Res, 2015; 40(12):2583–2599; doi: 10.1007/s11064-015-1581-6
31.
IliffJJ, ChenMJ, PlogBA, et al.Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. J Neurosci, 2014; 34(49):16180–16193; doi: 10.1523/JNEUROSCI.3020-14.2014
32.
ShiM, ShengL, StewartT, et al.New windows into the brain: Central nervous system-derived extracellular vesicles in blood. Prog Neurobiol, 2019; 175:96–106; doi: 10.1016/j.pneurobio.2019.01.005
33.
ThelinEP, TajsicT, ZeilerFA, et al.Monitoring the neuroinflammatory response following acute brain injury. Front Neurol, 2017; 8:351; doi: 10.3389/fneur.2017.00351
34.
ThelinEP, ZeilerFA, ErcoleA, et al.Serial sampling of serum protein biomarkers for monitoring human traumatic brain injury dynamics: A systematic review. Front Neurol, 2017; 8:300; doi: 10.3389/fneur.2017.00300
35.
MondelloS, SorinolaA, CzeiterE, et al.Blood-based protein biomarkers for the management of traumatic brain injuries in adults presenting to emergency departments with mild brain injury: A living systematic review and meta-analysis. J Neurotrauma, 2021; 38(8):1086–1106; doi: 10.1089/neu.2017.5182
36.
PetersAJ, SchnellE, SaugstadJA, et al.Longitudinal course of traumatic brain injury biomarkers for the prediction of clinical outcomes: A review. J Neurotrauma, 2021; 38(18):2490–2501; doi: 10.1089/neu.2020.7448
37.
VisserK, KoggelM, BlaauwJ, et al.Blood-based biomarkers of inflammation in mild traumatic brain injury: A systematic review. Neurosci Biobehav Rev, 2022; 132:154–168; doi: 10.1016/j.neubiorev.2021.11.036
38.
WhitehouseDP, VileAR, AdatiaK, et al.Blood biomarkers and structural imaging correlations post-traumatic brain injury: A systematic review. Neurosurgery, 2022; 90(2):170–179; doi: 10.1227/NEU.0000000000001776
39.
FeinbergC, MayesKD, PortmanE, et al.Non-invasive fluid biomarkers in the diagnosis of mild traumatic brain injury (mTBI): A systematic review. J Neurol Neurosurg Psychiatry, 2024; 95(2):184–192; doi: 10.1136/jnnp-2023-331220
40.
ZetterbergH, BlennowK. Fluid biomarkers for mild traumatic brain injury and related conditions. Nat Rev Neurol, 2016; 12(10):563–574; doi: 10.1038/nrneurol.2016.127
41.
NewcombeV, RichterS, WhitehouseDP, et al.Fluid biomarkers and neuroimaging in mild traumatic brain injury: Current uses and potential future directions for clinical use in emergency medicine. Emerg Med J, 2023; 40(9):671–677; doi: 10.1136/emermed-2023-213111
42.
Al-AdliN, AkbikOS, RailB, et al.The clinical use of serum biomarkers in traumatic brain injury: A systematic review stratified by injury severity. World Neurosurg, 2021; 155:e418–e438; doi: 10.1016/j.wneu.2021.08.073
43.
BrettBL, GardnerRC, GodboutJ, et al.Traumatic brain injury and risk of neurodegenerative disorder. Biol Psychiatry, 2022; 91(5):498–507; doi: 10.1016/j.biopsych.2021.05.025
44.
SwaneyEEK, CaiT, SealML, et al.Blood biomarkers of secondary outcomes following concussion: A systematic review. Front Neurol, 2023; 14:989974; doi: 10.3389/fneur.2023.989974
45.
O‘ConnellB, KellyÁM, MocklerD, et al.Use of blood biomarkers in the assessment of sports-related concussion-a systematic review in the context of their biological significance. Clin J Sport Med, 2018; 28(6):561–571; doi: 10.1097/JSM.0000000000000478
46.
MozaffariK, DejamD, DuongC, et al.Systematic review of serum biomarkers in traumatic brain injury. Cureus, 2021; 13(8):e17056; doi: 10.7759/cureus.17056
47.
GerberKS, AlvarezG, AlamianA, et al.Biomarkers of neuroinflammation in traumatic brain injury. Clin Nurs Res, 2022; 31(7):1203–1218; doi: 10.1177/10547738221107081
48.
PageMJ, MoherD, BossuytPM, et al.PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. Bmj, 2021; 372:n160; doi: 10.1136/bmj.n160
Dams-O‘ConnorK, CantorJB, BrownM, et al.Screening for traumatic brain injury: Findings and public health implications. J Head Trauma Rehabil, 2014; 29(6):479–489; doi: 10.1097/HTR.0000000000000099
51.
The Joanna Briggs Institute. Critical Appriasal Tools. The Joanna Briggs Institute: Adelaide, South Australia; 2017.
52.
HicksAJ, ClayFJ, JamesAC, et al.Effectiveness of pharmacotherapy for depression after adult traumatic brain injury: An umbrella review. Neuropsychol Rev, 2023; 33(2):393–431; doi: 10.1007/s11065-022-09543-6
53.
ShahimP, PolitisA, van der MerweA, et al.Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI. Neurology, 2020; 95(6):e623–e636; doi: 10.1212/WNL.0000000000009985
54.
ShahimP, PolitisA, van der MerweA, et al.Neurofilament light as a biomarker in traumatic brain injury. Neurology, 2020; 95(6):e610–e622; doi: 10.1212/WNL.0000000000009983
55.
CarrollLJ, CassidyJD, PelosoPM, et al;WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. Prognosis for mild traumatic brain injury: Results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med, 2004(43 Suppl):84–105.
56.
BagnatoS, AndrioloM, BoccagniC, et al.Reduced neuron-specific enolase levels in chronic severe traumatic brain injury. J Neurotrauma, 2020; 37(2):423–427; doi: 10.1089/neu.2019.6449
57.
ChabanV, ClarkeGJB, SkandsenT, et al.Systemic inflammation persists the first year after mild traumatic brain injury: Results from the prospective trondheim mild traumatic brain injury study. J Neurotrauma, 2020; 37(19):2120–2130.
58.
ClarkeGJB, SkandsenT, ZetterbergH, et al.One-year prospective study of plasma biomarkers from CNS in patients with mild traumatic brain injury. Front Neurol, 2021; 12:643743; doi: 10.3389/fneur.2021.643743
59.
DicksteinDL, De GasperiR, Gama SosaMA, et al.Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes following blast exposure. Mol Psychiatry, 2021; 26(10):5940–5954; doi: 10.1038/s41380-020-0674-z
60.
FlynnS, LeeteJ, ShahimP, et al.Extracellular vesicle concentrations of glial fibrillary acidic protein and neurofilament light measured 1 year after traumatic brain injury. Sci Rep, 2021; 11(1):3896; doi: 10.1038/s41598-021-82875-0
61.
GhaiV, FallenS, BaxterD, et al.Alterations in plasma microRNA and protein levels in war veterans with chronic mild traumatic brain injury. J Neurotrauma, 2020; 37(12):1418–1430.
62.
Gonzalez-OrtizF, DulewiczM, AshtonNJ, et al.Association of serum brain-derived tau with clinical outcome and longitudinal change in patients with severe traumatic brain injury. JAMA Netw Open, 2023; 6(7):e2321554; doi: 10.1001/jamanetworkopen.2023.21554
63.
GrahamN, ZimmermanKA, MoroF, et al.Axonal marker neurofilament light predicts long-term outcomes and progressive neurodegeneration after traumatic brain injury. Sci Transl Med, 2021; 13(613):eabg9922; doi: 10.1126/scitranslmed.abg9922
64.
GuedesVA, LangeRT, LippaSM, et al.Extracellular vesicle neurofilament light is elevated within the first 12-months following traumatic brain injury in a U.S military population. Sci Rep, 2022; 12(1):4002.
65.
JamesSN, NicholasJM, LaneCA, et al.A population-based study of head injury, cognitive function and pathological markers. Ann Clin Transl Neurol, 2021; 8(4):842–856.
66.
JuengstSB, KumarRG, ArenthPM, et al.Exploratory associations with tumor necrosis factor-alpha, disinhibition and suicidal endorsement after traumatic brain injury. Brain Behav Immun, 2014; 41:134–143.
67.
KorshnyakVO, BovtJV, PulykOR, et al.Mine-Blast trauma as a factor in the early development of vascular diseases of the brain. Wiad Lek, 2023; 76(6):1485–1490.
68.
KumarRG, BolesJA, WagnerAK. Chronic inflammation after severe traumatic brain injury: Characterization and associations with outcome at 6 and 12 months postinjury. J Head Trauma Rehabil, 2015; 30(6):369–381.
69.
LekomtsevaY. Targeting higher levels of lactate in the post-injury period following traumatic brain injury. Clin Neurol Neurosurg, 2020; 196:106050.
70.
LippaSM, LangeRT, DalgardCL, et al.APOE is associated with serum Tau following uncomplicated mild traumatic brain injury. Front Neurol, 2022; 13:816625.
71.
LippaSM, GillJ, BrickellTA, et al.Blood biomarkers relate to cognitive performance years after traumatic brain injury in service members and veterans. J Int Neuropsychol Soc, 2021; 27(5):508–514.
72.
McDonaldSJ, PiantellaS, O’BrienWT, et al.Clinical and blood biomarker trajectories after concussion: New insights from a longitudinal pilot study of professional flat-track Jockeys. J Neurotrauma, 2023; 40(1–2):52–62.
73.
NeedhamEJ, StoevesandtO, ThelinEP, et al.Complex autoantibody responses occur following moderate to severe traumatic brain injury. J Immunol, 2021; 207(1):90–100.
74.
NewcombeVFJ, AshtonNJ, PostiJP, et al.Post-acute blood biomarkers and disease progression in traumatic brain injury. Brain, 2022; 145(6):2064–2076; doi: 10.1093/brain/awac126
75.
OwensTS, MarleyCJ, CalverleyTA, et al.Lower systemic nitric oxide bioactivity, cerebral hypoperfusion and accelerated cognitive decline in formerly concussed retired rugby union players. Exp Physiol, 2023; 108(8):1029–1046; doi: 10.1113/EP091195
76.
PavlovicD, PekicS, StojanovicM, et al.Chronic cognitive sequelae after traumatic brain injury are not related to growth hormone deficiency in adults. Eur J Neurol, 2010; 17(5):696–702; doi: 10.1111/j.1468-1331.2009.02910.x
77.
PowellJR, BoltzAJ, DeCiccoJP, et al.Neuroinflammatory biomarkers associated with mild traumatic brain injury history in special operations forces combat soldiers. J Head Trauma Rehabil, 2020; 35(5):300–307; doi: 10.1097/HTR.0000000000000598
78.
SchnakersC, DivineJ, JohnsonMA, et al.Longitudinal changes in blood-based biomarkers in chronic moderate to severe traumatic brain injury: Preliminary findings. Brain Inj, 2021; 35(3):285–291.
79.
ShahimP, GrenM, LimanV, et al.Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci Rep, 2016; 6:36791; doi: 10.1038/srep36791
80.
WernerJK, ShahimP, PucciJU, et al.Poor sleep correlates with biomarkers of neurodegeneration in mild traumatic brain injury patients: A CENC study. Sleep, 2021; 44(6):11.
81.
WilliamsSM, PeltzC, YaffeK, et al.CNS disease-related protein variants as blood-based biomarkers in traumatic brain injury. Neurology, 2018; 91(15):702–709; doi: 10.1212/WNL.0000000000006322
82.
GottshallJL, GuedesVA, PucciJU, et al.Poor sleep quality is linked to elevated extracellular vesicle-associated inflammatory cytokines in warfighters with chronic mild traumatic brain injuries. Front Pharmacol, 2021; 12:762077; doi: 10.3389/fphar.2021.762077
83.
FaillaMD, JuengstSB, ArenthPM, et al.Preliminary associations between brain-derived neurotrophic factor, memory impairment, functional cognition, and depressive symptoms following severe TBI. Neurorehabil Neural Repair, 2016; 30(5):419–430.
84.
ChenX-H, JohnsonVE, UryuK, et al.A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. Brain Pathol, 2009; 19(2):214–223; doi: 10.1111/j.1750-3639.2008.00176.x
85.
JohnsonVE, StewartJE, BegbieFD, et al.Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain, 2013; 136(Pt 1):28–42; doi: 10.1093/brain/aws322
86.
RamlackhansinghAF, BrooksDJ, GreenwoodRJ, et al.Inflammation after trauma: Microglial activation and traumatic brain injury. Ann Neurol, 2011; 70(3):374–383; doi: 10.1002/ana.22455
87.
MarklundN, VedungF, LubberinkM, et al.Tau aggregation and increased neuroinflammation in athletes after sports-related concussions and in traumatic brain injury patients - A PET/MR study. Neuroimage Clin, 2021; 30:102665; doi: 10.1016/j.nicl.2021.102665
88.
GentlemanSM, LeclercqPD, MoyesL, et al.Long-term intracerebral inflammatory response after traumatic brain injury. Forensic Sci Int, 2004; 146(2–3):97–104; doi: 10.1016/j.forsciint.2004.06.027
89.
LucasS-M, RothwellNJ, GibsonRM. The role of inflammation in CNS injury and disease. Br J Pharmacol, 2006; 147(Suppl 1):S232–S40; doi: 10.1038/sj.bjp.0706400
90.
Kokiko-CochranON, GodboutJP. The inflammatory continuum of traumatic brain injury and alzheimer’s disease. Front Immunol, 2018; 9:672; doi: 10.3389/fimmu.2018.00672
91.
SteinDM, LindellAL, MurdockKR, et al.Use of serum biomarkers to predict cerebral hypoxia after severe traumatic brain injury. J Neurotrauma, 2012; 29(6):1140–1149; doi: 10.1089/neu.2011.2149
92.
ThelinEP, JeppssonE, FrostellA, et al.Utility of neuron-specific enolase in traumatic brain injury; relations to S100B levels, outcome, and extracranial injury severity. Crit Care, 2016; 20:285; doi: 10.1186/s13054-016-1450-y
93.
ChabokSY, MoghadamAD, SaneeiZ, et al.Neuron-specific enolase and S100BB as outcome predictors in severe diffuse axonal injury. J Trauma Acute Care Surg, 2012; 72(6):1654–1657; doi: 10.1097/TA.0b013e318246887e
94.
ChengF, YuanQ, YangJ, et al.The prognostic value of serum neuron-specific enolase in traumatic brain injury: Systematic review and meta-analysis. PLoS One, 2014; 9(9):e106680; doi: 10.1371/journal.pone.0106680
GorgoraptisN, LiLM, WhittingtonA, et al.In vivo detection of cerebral tau pathology in long-term survivors of traumatic brain injury. Sci Transl Med, 2019; 11(508):eaaw1993; doi: 10.1126/scitranslmed.aaw1993
97.
JohnsonVE, StewartW, SmithDH. Widespread τ and amyloid-β pathology many years after a single traumatic brain injury in humans. Brain Pathol, 2012; 22(2):142–149; doi: 10.1111/j.1750-3639.2011.00513.x
98.
Castaño-LeonAM, CicuendezM, NavarroB, et al.Longitudinal analysis of corpus callosum diffusion tensor imaging metrics and its association with neurological outcome. J Neurotrauma, 2019; 36(19):2785–2802; doi: 10.1089/neu.2018.5978
99.
NewcombeVFJ, CorreiaMM, LedigC, et al.Dynamic changes in white matter abnormalities correlate with late improvement and deterioration following TBI: A diffusion tensor imaging study. Neurorehabil Neural Repair, 2016; 30(1):49–62; doi: 10.1177/1545968315584004
100.
KenneyK, IaconoD, EdlowBL, et al.Dementia after moderate-severe traumatic brain injury: Coexistence of multiple proteinopathies. J Neuropathol Exp Neurol, 2018; 77(1):50–63; doi: 10.1093/jnen/nlx101
101.
WojkowskaDW, SzpakowskiP, GlabinskiA. Interleukin 17A promotes lymphocytes adhesion and induces CCL2 and CXCL1 release from brain endothelial cells. Int J Mol Sci, 2017; 18(5); doi: 10.3390/ijms18051000
102.
ChenJ, HuJ, LiuH, et al.FGF21 protects the blood-brain barrier by upregulating PPARγ via FGFR1/β-klotho after traumatic brain injury. J Neurotrauma, 2018; 35(17):2091–2103; doi: 10.1089/neu.2017.5271
PuntambekarSS, SaberM, LambBT, et al.Cellular players that shape evolving pathology and neurodegeneration following traumatic brain injury. Brain Behav Immun, 2018; 71:9–17; doi: 10.1016/j.bbi.2018.03.033
105.
WoodcockT, Morganti-KossmannMC. The role of markers of inflammation in traumatic brain injury. Front Neurol, 2013; 4:18; doi: 10.3389/fneur.2013.00018
106.
ZiebellJM, Morganti-KossmannMC. Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics, 2010; 7(1):22–30; doi: 10.1016/j.nurt.2009.10.016
107.
GuoY, HuangY-Y, ShenX-N, et al;Alzheimer’s Disease Neuroimaging Initiative. Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF, and PET. Alzheimers Res Ther, 2021; 13(1):93; doi: 10.1186/s13195-021-00834-3
108.
BraakH, ThalDR, GhebremedhinE, et al.Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. J Neuropathol Exp Neurol, 2011; 70(11):960–969; doi: 10.1097/NEN.0b013e318232a379
109.
ChiuM-J, FanL-Y, ChenT-F, et al.Plasma Tau levels in cognitively normal middle-aged and older adults. Front Aging Neurosci, 2017; 9:51; doi: 10.3389/fnagi.2017.00051
110.
DisantoG, BarroC, BenkertP, et al;Swiss Multiple Sclerosis Cohort Study Group. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol, 2017; 81(6):857–870; doi: 10.1002/ana.24954
MattsonMP, ArumugamTV. Hallmarks of brain aging: Adaptive and pathological modification by metabolic states. Cell Metab, 2018; 27(6):1176–1199; doi: 10.1016/j.cmet.2018.05.011
GardnerRC, RubensteinR, WangKKW, et al.Age-related differences in diagnostic accuracy of plasma glial fibrillary acidic protein and Tau for identifying acute intracranial trauma on computed tomography: A TRACK-TBI Study. J Neurotrauma, 2018; 35(20):2341–2350; doi: 10.1089/neu.2018.5694
115.
CalcagnileO, HolménA, ChewM, et al.S100B levels are affected by older age but not by alcohol intoxication following mild traumatic brain injury. Scand J Trauma Resusc Emerg Med, 2013; 21:52; doi: 10.1186/1757-7241-21-52
116.
IversonGL, ReddiPJ, PostiJP, et al.Serum neurofilament light is elevated differentially in older adults with uncomplicated mild traumatic brain injuries. J Neurotrauma, 2019; 36(16):2400–2406; doi: 10.1089/neu.2018.6341
117.
SnairM, MatneyC, BowmanK, et al.Biomarkers for traumatic brain injury. In: Proceedings of a Workshop. 2023; doi: 10.1722/6/26932
118.
MellergårdP, ÅnemanO, SjögrenF, et al.Differences in cerebral extracellular response of interleukin-1β, interleukin-6, and interleukin-10 after subarachnoid hemorrhage or severe head trauma in humans. Neurosurgery, 2011; 68(1):12–19; discussion 19; doi: 10.1227/NEU.0b013e3181ef2a40
119.
XiongY, MahmoodA, ChoppM. Current understanding of neuroinflammation after traumatic brain injury and cell-based therapeutic opportunities. Chin J Traumatol, 2018; 21(3):137–151; doi: 10.1016/j.cjtee.2018.02.003
120.
Di BattistaAP, ChurchillN, RhindSG, et al.The relationship between symptom burden and systemic inflammation differs between male and female athletes following concussion. BMC Immunol, 2020; 21(1):11; doi: 10.1186/s12865-020-0339-3
121.
CorriganJD, HammondFM, SanderA, et al.Recognition of traumatic brain injury as a chronic condition: A commentary. J Neurotrauma, 2024; 41(23–24):2602–2605; doi: 10.1089/neu.2024.0356
122.
DellKC, GrossnerEC, StaphJ, et al.A population-based study of pre-existing health conditions in traumatic brain injury. Neurotrauma Rep, 2021; 2(1):255–269; doi: 10.1089/neur.2020.0065
123.
KumarRG, JuengstSB, WangZ, et al.Epidemiology of comorbid conditions among adults 50 years and older with traumatic brain injury. J Head Trauma Rehabil, 2018; 33(1):15–24; doi: 10.1097/HTR.0000000000000273
124.
DreerLE, KetchumJM, NovackTA, et al.Obesity and overweight problems among individuals 1 to 25 years following acute rehabilitation for traumatic brain injury: A NIDILRR traumatic brain injury model systems study. J Head Trauma Rehabil, 2018; 33(4):246–256; doi: 10.1097/HTR.0000000000000408
125.
AlwayY, GouldKR, JohnstonL, et al.A prospective examination of Axis I psychiatric disorders in the first 5 years following moderate to severe traumatic brain injury. Psychol Med, 2016; 46(6):1331–1341; doi: 10.1017/S0033291715002986
126.
OsbornAJ, MathiasJL, Fairweather-SchmidtAK, et al.Anxiety and comorbid depression following traumatic brain injury in a community-based sample of young, middle-aged and older adults. J Affect Disord, 2017; 213:214–221; doi: 10.1016/j.jad.2016.09.045
127.
BombardierCH, FannJR, TemkinNR, et al.Rates of major depressive disorder and clinical outcomes following traumatic brain injury. JAMA, 2010; 303(19):1938–1945; doi: 10.1001/jama.2010.599
128.
HammondFM, CorriganJD, KetchumJM, et al.Prevalence of medical and psychiatric comorbidities following traumatic brain injury. J Head Trauma Rehabil, 2019; 34(4):E1–E10; doi: 10.1097/HTR.0000000000000465
129.
AmbatiA, JuY-E, LinL, et al.Proteomic biomarkers of sleep apnea. Sleep, 2020; 43(11); doi: 10.1093/sleep/zsaa086
130.
DikeosD, WichniakA, KtonasPY, et al.The potential of biomarkers for diagnosing insomnia: Consensus statement of the WFSBP Task Force on Sleep Disorders. World J Biol Psychiatry, 2023; 24(8):614–642; doi: 10.1080/15622975.2023.2171479
131.
NguyenLT, SharmaAR, ChakrabortyC, et al.Review of prospects of biological fluid biomarkers in osteoarthritis. Int J Mol Sci, 2017; 18(3); doi: 10.3390/ijms18030601
132.
PreeceRL, HanSYS, BahnS. Proteomic approaches to identify blood-based biomarkers for depression and bipolar disorders. Expert Rev Proteomics, 2018; 15(4):325–340; doi: 10.1080/14789450.2018.1444483
133.
PierceME, HayesJ, HuberBR, et al.Plasma biomarkers associated with deployment trauma and its consequences in post-9/11 era veterans: Initial findings from the TRACTS longitudinal cohort. Transl Psychiatry, 2022; 12(1):80.
134.
HierDB, Obafemi-AjayiT, ThimganMS, et al.Blood biomarkers for mild traumatic brain injury: A selective review of unresolved issues. Biomark Res, 2021; 9(1):70; doi: 10.1186/s40364-021-00325-5
135.
HuibregtseME, BazarianJJ, ShultzSR, et al.The biological significance and clinical utility of emerging blood biomarkers for traumatic brain injury. Neurosci Biobehav Rev, 2021; 130:433–447; doi: 10.1016/j.neubiorev.2021.08.029
136.
MoscosoA, GrotheMJ, AshtonNJ, et al;Alzheimer’s Disease Neuroimaging Initiative. Longitudinal associations of blood phosphorylated Tau181 and Neurofilament Light chain with neurodegeneration in alzheimer disease. JAMA Neurol, 2021; 78(4):396–406; doi: 10.1001/jamaneurol.2020.4986
137.
PiantinoJ, SchwartzDL, LutherM, et al.Link between mild traumatic brain injury, poor sleep, and magnetic resonance imaging: Visible perivascular spaces in veterans. J Neurotrauma, 2021; 38(17):2391–2399; doi: 10.1089/neu.2020.7447
138.
OpelRA, ChristyA, BoespflugEL, et al.Effects of traumatic brain injury on sleep and enlarged perivascular spaces. J Cereb Blood Flow Metab, 2019; 39(11):2258–2267; doi: 10.1177/0271678X18791632
139.
IliffJJ, WangM, LiaoY, et al.A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med, 2012; 4(147):147ra111; doi: 10.1126/scitranslmed.3003748
140.
XieL, KangH, XuQ, et al.Sleep drives metabolite clearance from the adult brain. Science, 2013; 342(6156):373–377; doi: 10.1126/science.1241224
141.
MiaoA, LuoT, HsiehB, et al.Brain clearance is reduced during sleep and anesthesia. Nat Neurosci, 2024; 27(7):1425; doi: 10.1038/s41593-024-01638-y
142.
Del BruttoOH, MeraRM, Del BruttoVJ, et al.Enlarged basal ganglia perivascular spaces and sleep parameters. A population-based study. Clin Neurol Neurosurg, 2019; 182:53–57; doi: 10.1016/j.clineuro.2019.05.002
143.
HicksA, SinclairB, ShultzS, et al.Associations of enlarged perivascular spaces with brain lesions, brain age, and clinical outcomes in chronic traumatic brain injury. Neurology, 2023; 101(1):e63–e73; doi: 10.1212/WNL.0000000000207370
144.
WangM-L, YangD-X, SunZ, et al.MRI-Visible perivascular spaces associated with cognitive impairment in military veterans with traumatic brain injury mediated by CSF P-Tau. Front Psychiatry, 2022; 13:921203; doi: 10.3389/fpsyt.2022.921203
145.
PlogBA, DashnawML, HitomiE, et al.Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. J Neurosci, 2015; 35(2):518–526; doi: 10.1523/JNEUROSCI.3742-14.2015
146.
McDonaldSJ, ShultzSR, AgostonDV. The known unknowns: An overview of the state of blood-based protein biomarkers of mild traumatic brain injury. J Neurotrauma, 2021; 38(19):2652–2666; doi: 10.1089/neu.2021.0011
147.
ManleyGT, Diaz-ArrastiaR, BrophyM, et al.Common data elements for traumatic brain injury: Recommendations from the biospecimens and biomarkers working group. Arch Phys Med Rehabil, 2010; 91(11):1667–1672; doi: 10.1016/j.apmr.2010.05.018
148.
CsukaE, Morganti-KossmannMC, LenzlingerPM, et al.IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: Relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain barrier function. J Neuroimmunol, 1999; 101(2):211–221.
149.
BlythBJ, FarhavarA, GeeC, et al.Validation of serum markers for blood-brain barrier disruption in traumatic brain injury. J Neurotrauma, 2009; 26(9):1497–1507; doi: 10.1089/neu.2008.0738
150.
SawMM, ChamberlainJ, BarrM, et al.Differential disruption of blood-brain barrier in severe traumatic brain injury. Neurocrit Care, 2014; 20(2):209–216; doi: 10.1007/s12028-013-9933-z
151.
TomkinsO, FeintuchA, BeniflaM, et al.Blood-brain barrier breakdown following traumatic brain injury: A possible role in posttraumatic epilepsy. Cardiovasc Psychiatry Neurol, 2011; 2011:765923; doi: 10.1155/2011/765923
152.
HayJR, JohnsonVE, YoungAMH, et al.Blood-Brain barrier disruption is an early event that may persist for many years after traumatic brain injury in humans. J Neuropathol Exp Neurol, 2015; 74(12):1147–1157; doi: 10.1097/NEN.0000000000000261
153.
SawMM, ChamberlainJ, BarrM, et al.Differential disruption of blood-brain barrier in severe traumatic brain injury. Neurocrit Care, 2014; 20(2):209–216; doi: 10.1007/s12028-013-9933-z
154.
TomkinsO, FeintuchA, BeniflaM, et al.Blood-brain barrier breakdown following traumatic brain injury: A possible role in posttraumatic epilepsy. Cardiovasc Psychiatry Neurol, 2011; 2011:765923; doi: 10.1155/2011/765923
155.
HayJR, JohnsonVE, YoungAMH, et al.Blood-Brain barrier disruption is an early event that may persist for many years after traumatic brain injury in humans. J Neuropathol Exp Neurol, 2015; 74(12):1147–1157; doi: 10.1097/NEN.0000000000000261
156.
EdalatfarM, PiriSM, MehrabinejadM-M, et al.Biofluid biomarkers in traumatic brain injury: A systematic scoping review. Neurocrit Care, 2021; 35(2):559–572; doi: 10.1007/s12028-020-01173-1
157.
HuieJR, Diaz-ArrastiaR, YueJK, et al;TRACK-TBI Investigators. Testing a multivariate proteomic panel for traumatic brain injury biomarker discovery: A TRACK-TBI pilot study. J Neurotrauma, 2019; 36(1):100–110; doi: 10.1089/neu.2017.5449
158.
WildeEA, WannerI-B, KenneyK, et al.A framework to advance biomarker development in the diagnosis, outcome prediction, and treatment of traumatic brain injury. J Neurotrauma, 2022; 39(7–8):436–457; doi: 10.1089/neu.2021.0099
159.
MalecJF, BrownAW, LeibsonCL, et al.The mayo classification system for traumatic brain injury severity. J Neurotrauma, 2007; 24(9):1417–1424.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
